Anti-Cannabinoid Receptor-1, CT (CB1)

Cannabinoids, are a group of C21 compounds present in Cannabis sativa L.. Their carboxylic acids, analogs and transformation products are the active ingredients found in hasish and marihuana. (-)-trans-D9-tetrahydrocannabinol (D9-THC) is the major psychopharmacologically active component of cannabis. Cannabis affects cognition and memory, euphoria and sedation, and antinociception (analgesia) without the respiratory depression problems associated with opioid analgesics. D9-THC is also immunosuppressive. It impairs cell-mediated immunity, humoral immunity and cellular defenses against a variety of infectious agents both in vivo and in vitro. To date, two subtypes of the G-protein coupled cannabinoid receptor, CB1 and CB2, have been identified. The first brain-derived endogenous cannabinoids, an unsaturated fatty-acid ethanolamide, arachidonylethanolamide (AEA, also called anandamide) was found in brain. AEA has higher affinity for the CB1 than for the CB2. CB1(rat/mouse 473aa, human 472aa, ~95% sequence homology) has 7 TM domains with an extracellular N-terminus and cytoplasmic C-terminus. An alternative spliced N-terminal variant, CB1A, has also been reported. The CB1 receptor has been shown to inhibit adenylate cyclase activity in a pertussis-toxin sensitive manner and to be more responsive to psychoactive cannabinoids than to non-psychoactive cannabinoids. CB1 couples to a pertussis-toxin sensitive G-protein to regulate Ca2+ currents, to activate inward rectifying K+ channels and to activate MAP Kinases. CB1 receptor is distributed throughout the brain, with higher representation in the hippocampus, a brain region essential for storage of newly acquired information and changes of mood and behavioral state. In the cerebellum, CB1 is most dense in the molecular layer, consistent with the effects of cannabinoids on the coordination of motor function and motor learning. Applications: Suitable for use in Western Blot and ELISA. Other applications have not been tested. Recommended Dilution: Western Blot: 1-10ug/ml using ECL (~60kD and 80-84kD under reducing conditions), ELISA: 1:10,000-1:100,000 using 50-100ng control peptide, Optimal dilutions to be determined by the researcher. Control Peptide: C1075-71A Cannabinoid Receptor 1, CT, Control Peptide (CB1), Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile 40-50% glycerol and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.